Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies

Firestein, 2012, Etiology and pathogenesis of rheumatoid arthritis, vol 2, 1059 Firestein, 2003, Evolving concepts of rheumatoid arthritis, Nature, 423, 356, 10.1038/nature01661 Murphy, 2008, Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?, Nat Clin Pract Rheumatol, 4, 128, 10.1038/ncprheum0727 Edwards, 2008, The ADAM metalloproteinases, Mol Aspects Med, 29, 258, 10.1016/j.mam.2008.08.001 Taylor, 2009, Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nat Rev Rheumatol, 5, 578, 10.1038/nrrheum.2009.181 Dayer, 2010, Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor, Rheumatology (Oxford), 49, 15, 10.1093/rheumatology/kep329 Scheller, 2011, ADAM17: a molecular switch to control inflammation and tissue regeneration, Trends Immunol, 32, 380, 10.1016/j.it.2011.05.005 Mezyk-Kopec, 2009, Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts, Cytokine, 46, 309, 10.1016/j.cyto.2009.03.002 Arduise, 2008, Tetraspanins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal growth factor, J Immunol, 181, 7002, 10.4049/jimmunol.181.10.7002 Condon, 2001, ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes, Antisense Nucleic Acid Drug Dev, 11, 107, 10.1089/108729001750171353 Sakamoto, 2009, Cytoplasmic tail of MT1-MMP regulates macrophage motility independently from its protease activity, Genes Cells, 14, 617, 10.1111/j.1365-2443.2009.01293.x Sledge, 2001, Biology of the normal joint, 1 Heinegård, 2001, Matrix glycoproteins, proteoglycans, and cartilage, 41 Chandler, 1996, Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein, Biochem Biophys Res Commun, 228, 421, 10.1006/bbrc.1996.1677 Shipley, 1996, Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice, Proc Natl Acad Sci U S A, 93, 3942, 10.1073/pnas.93.9.3942 Wang, 2004, Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits, Am J Pathol, 165, 1375, 10.1016/S0002-9440(10)63395-0 Koshy, 2002, The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction, Arthritis Rheum, 46, 961, 10.1002/art.10212 van Lent, 2008, Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis, Ann Rheum Dis, 67, 1750, 10.1136/ard.2007.077800 van Lent, 2008, Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis, Arthritis Rheum, 58, 3776, 10.1002/art.24074 Fearon, 2006, Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures, Arthritis Rheum, 54, 3152, 10.1002/art.22161 Konttinen, 1999, Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate, Matrix Biol, 18, 401, 10.1016/S0945-053X(99)00030-X Jüngel, 2010, Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis, Ann Rheum Dis, 69, 898, 10.1136/ard.2008.106021 Konttinen, 1999, Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis, Ann Rheum Dis, 58, 691, 10.1136/ard.58.11.691 Pap, 2000, Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis, Arthritis Rheum, 43, 1226, 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4 Konttinen, 1998, New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above, Matrix Biol, 17, 585, 10.1016/S0945-053X(98)90110-X Miller, 2009, Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis, Arthritis Rheum, 60, 686, 10.1002/art.24331 Sabeh, 2010, Membrane-type I matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function, J Immunol, 184, 6396, 10.4049/jimmunol.0904068 Kaneko, 2016, Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of experimental inflammatory arthritis: synergy with tumor necrosis factor blockade, Arthritis Rheumatol, 68, 521, 10.1002/art.39414 Zhou, 2000, Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I, Proc Natl Acad Sci U S A, 97, 4052, 10.1073/pnas.060037197 Matias-Roman, 2005, Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium, Blood, 105, 3956, 10.1182/blood-2004-06-2382 Sithu, 2007, Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration, J Biol Chem, 282, 25010, 10.1074/jbc.M611273200 Gendron, 2007, Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4, J Biol Chem, 282, 18294, 10.1074/jbc.M701523200 Stanton, 2005, ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro, Nature, 434, 648, 10.1038/nature03417 Little, 2007, Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair, J Clin Invest, 117, 1627, 10.1172/JCI30765 Feldmann, 2015, Perspectives from masters in rheumatology and autoimmunity: can we get closer to a cure for rheumatoid arthritis?, Arthritis Rheumatol, 67, 2283, 10.1002/art.39269 Genovese, 2004, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate, Arthritis Rheum, 50, 1412, 10.1002/art.20221 Weinblatt, 2007, Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial, Ann Rheum Dis, 66, 228, 10.1136/ard.2006.055111 Alzabin, 2012, Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway, Ann Rheum Dis, 71, 1741, 10.1136/annrheumdis-2011-201024 Notley, 2008, Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells, J Exp Med, 205, 2491, 10.1084/jem.20072707 Genovese, 2014, A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors, Arthritis Rheumatol, 66, 1693, 10.1002/art.38617 Fingleton, 2008, MMP inhibitor clinical trials–the past, present, and future, 759 Jacobsen, 2010, To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition, Biochim Biophys Acta, 1803, 72, 10.1016/j.bbamcr.2009.08.006 Balbin, 2003, Loss of collagenase-2 confers increased skin tumor susceptibility to male mice, Nat Genet, 35, 252, 10.1038/ng1249 Cox, 2010, Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression, Arthritis Rheum, 62, 3645, 10.1002/art.27757 Itoh, 2002, The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis, J Immunol, 169, 2643, 10.4049/jimmunol.169.5.2643 Mudgett, 1998, Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction, Arthritis Rheum, 41, 110, 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G Clements, 2003, Arthritis Rheum, 48, 3452, 10.1002/art.11355 Marchant, 2014, A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity, Nat Med, 20, 493, 10.1038/nm.3508 Zheng, 2001, Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura, J Biol Chem, 276, 41059, 10.1074/jbc.C100515200 Levy, 2001, Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura, Nature, 413, 488, 10.1038/35097008 Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res, 69, 1517, 10.1158/0008-5472.CAN-08-3255 Botkjaer, 2016, Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo, Oncotarget, 7, 16773, 10.18632/oncotarget.7780 Udi, 2015, Inhibition mechanism of membrane metalloprotease by an exosite-swiveling conformational antibody, Structure, 23, 104, 10.1016/j.str.2014.10.012 Galvez, 2001, Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling, J Biol Chem, 276, 37491, 10.1074/jbc.M104094200 Talmi-Frank, 2016, Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality, Cell Host Microbe, 20, 458, 10.1016/j.chom.2016.09.005 Remacle, 2017, Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis, Oncotarget, 8, 2781, 10.18632/oncotarget.13157 Tape, 2011, Cross-domain inhibition of TACE ectodomain, Proc Natl Acad Sci U S A, 108, 5578, 10.1073/pnas.1017067108 Caiazza, 2015, Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells, Br J Cancer, 112, 1895, 10.1038/bjc.2015.163 Santamaria, 2015, Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2), Biochem J, 471, 391, 10.1042/BJ20150758